DOI: http://dx.doi.org/10.18203/2349-3291.ijcp20204042

Conventional audiometric screening for detection of drug induced hearing loss in thalassemics: a pilot study

Vikram Bharadwaj, Manish Munjal, Parth Chopra, Shubham Munjal, Sivjot Binepal, Hemant Chopra, Praveen Sobti

Abstract


Background: Drug induced hearing impairment is likely in subjects undergoing multiple blood transfusions which necessitates timely detection and rehabilitation, especially in the pediatric age group.

Methods: A total 30 thalassemic patients undergoing regular iron chelation therapy with Desferrioxamine and Deferasirox were included in this prospective study. Follow up studies were conducted after 12 months of chelation therapy i.e. after 1 year thus spanning a total duration of 1 years.

Results: The most common age group was 4-8 years (46%) followed by 8-12 years (20%). Male patients outnumbered female patients in the ratio of 2.75:1 constituting 73% of study population oral Deferasirox (80%) followed Desferrioxamine (13.3%) and a combination therapy (6.6%). The distribution shows shift of pure tone average in higher thresholds with continuation of therapy.

Conclusion: Despite Desferrioxamine doses usually felt to be low risk for ototoxicity (less than 40 mg/kg/day), found a high rate of ototoxicity in our patients using pure tone audiometry (23%).


Keywords


Blood transfusion, Hearing impairment, Pure tone audiometry, Thalassemia

Full Text:

PDF

References


Styles LA, Vichinsky EP. Ototoxicity in hemoglobinopathy patients chelated with desferrioxamine. Journal of pediatric hematology/oncology. 1996;18(1):42-5.

Chen SH, Liang DC, Lin HC, Cheng SY, Chen LJ, Liu HC. Auditory and visual toxicity during deferoxamine therapy in transfusion-dependent patients. Journal of Pediatric Hematology/Oncology. 2005;27(12):651-3.

Karimi M, Asadi-Pooya AA, Khademi B, Asadi-Pooya K, Yarmohammadi H. Evaluation of the incidence of sensorineural hearing loss in beta-thalassemia major patients under regular chelation therapy with desferrioxamine. Acta haematologica. 2002;108(2):79-83.

Kontzoglou G, Koussi A, Economou M, Tsatra I, Perifanis V, Noussios G, et al. Long-term audiological evaluation of beta-thalassemic patients. Acta oto-rhino-laryngologica belgica. 2004;58(2):113.

Chiodo AA, Alberti PW, Sher GD, Francombe WH, Tyler B. Desferrioxamine ototoxicity in an adult transfusion-dependent population. Journal of otolaryngology. 1997;26(2).

Triantafyllou N, Fisfis M, Sideris G, Triantafyllou D, Rombos A, Vrettou H et al. Neurophysiological and neuro‐otological study of homozygous beta‐thalassemia under long‐term desferrioxamine (DFO) treatment. Acta neurologica scandinavica. 1991;83(5):306-8.

Ambrosetti U, Dondè E, Piatti G, Cappellini MD. Audiological evaluation in adult beta-thalassemia major patients under regular chelation treatment. Pharmacol Rese. 2000;42(5):485-7.

Olivieri NF, Buncic JR, Chew E, Gallant T, Harrison RV, Keenan N et al. Visual and auditory neurotoxicity in patients receiving subcutaneous deferoxamine infusions. New England J Med. 1986;314(14):869-73.

Albera R, Pia F, Morra B, Lacilla M, Bianco L, Gabutti V, Piga A. Hearing loss and desferrioxamine in homozygous beta-thalassemia. Audiology. 1988;27(4):207-14.

Porter JB, Jaswon MS, Huehns ER, East CA, Hazell JW. Desferrioxamine ototoxicity: evaluation of risk factors in thalassaemic patients and guidelines for safe dosage. Br J haematol. 1989;73(3):403-9.